Management of Diabetes in Organ Transplant Patients.
10.4093/jkd.2014.15.3.134
- Author:
Yujung YUN
1
;
Eun Seok KANG
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
- Publication Type:Editorial
- Keywords:
Diabetes mellitus;
Organ transplantation;
Risk factors;
Diagnosis;
Management
- MeSH:
Calcineurin;
Diabetes Mellitus;
Diagnosis;
Hepacivirus;
Humans;
Immunosuppressive Agents;
Mortality;
Organ Transplantation;
Risk Factors;
Transplants*
- From:Journal of Korean Diabetes
2014;15(3):134-141
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
New onset diabetes after transplantation (NODAT) is a common complication after solid-organ transplantation and is associated with increased cardiovascular morbidity, mortality, and graft loss. The risk factors for NODAT include older age, ethnicity, genetic factors,obesity, family history of diabetes, hepatitis C virus infection, and immunosuppressant use (corticosteroids, calcineurin inhibitors, and mTOR inhibitor). Management of NODAT must be considered at the pre-transplantation stage in order to properly screen high-risk patients. Although NODAT management is similar to that of general type 2 diabetes, some specific considerations must be made in NODAT management, including the interactions between anti-diabetes medication and immunosuppressive agents.
